GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Olink Holding AB (NAS:OLK) » Definitions » Valuation Rank

Olink Holding AB (Olink Holding AB) Valuation Rank


View and export this data going back to 2021. Start your Free Trial

What is Olink Holding AB Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

  1. Three factors:
    • Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
    • Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
    • Industry relative valuation
  2. Companies without enough data is not ranked
  3. Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.

Olink Holding AB Valuation Rank Related Terms

Thank you for viewing the detailed overview of Olink Holding AB's Valuation Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

Olink Holding AB (Olink Holding AB) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Olink Holding AB (NAS:OLK) » Definitions » Valuation Rank
Comparable Companies
GH NEOG SHC RDNT NEO NTRA MYGN OPK TWST FLGT TMO DHR SHSE:603259 IQV IDXX A XSWX:LONN MTD ICLR LH
Traded in Other Exchanges
6XA:Germany
Address
Uppsala Science Park, Uppsala, SWE, SE-75183
Website
https://www.olink.com
Olink Holding AB has a proprietary and patented Proximity Extension Assay technology, which enables researchers to use one platform for discovery to clinical trials to diagnostic applications utilizing the established infrastructure of labs and installed instrumentation. It has two segments including Kit and Services. It derives revenues from Sweden, the Americas, China, EMEA (Excluding Sweden) Japan, and other regions.